PMID- 20136960
OWN - NLM
STAT- MEDLINE
DCOM- 20100422
LR  - 20220330
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 24
IP  - 11
DP  - 2009 Nov
TI  - Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers 
      in the assessment of disease activity and severity in patients with idiopathic 
      ulcerative colitis.
PG  - 1768-74
LID - 10.1111/j.1440-1746.2009.06048.x [doi]
AB  - BACKGROUND AND AIM: Disease activity and severity of ulcerative colitis (UC) is 
      assessed using colonoscopy, which is invasive, costly and has poor patient 
      acceptability. The role of non-invasive biomarkers of intestinal inflammation in 
      the evaluation of patients with UC is not known. The aim of the study was to 
      examine the role of serum C-reactive protein (SCRP), fecal myeloperoxidase (FMPO) 
      and fecal lactoferrin (FLF) in assessing disease severity, activity and response 
      to therapy. METHODS: Consecutive patients with idiopathic UC (IUC) attending our 
      hospital from July 2005 to September 2006 were studied. All underwent clinical, 
      endoscopic and histological assessment for disease activity, extent, severity and 
      estimation of SCRP, FMPO and FLF levels at baseline and follow up (FU). An equal 
      number of healthy age-matched controls were studied for biomarker levels. 
      RESULTS: A total of 37 patients (mean age 37 +/- 12 years) were studied. All 
      three biomarkers were elevated more often in the cases than in the controls (all 
      P = 0.000). Cases with severe IUC had higher CRP, MPO and FLF titers than those 
      without severe IUC. At FU, a significant fall in biomarker levels paralleled the 
      reduction in Mayo's scores. All three biomarkers showed a high degree of 
      correlation with each other. The areas under the curve for FLF, MPO and CRP were 
      1.00, 0.867 and 0.622, respectively. The sensitivity and specificity of markers 
      were: FLF (94%, 100%), FMPO (89%, 51%) and SCRP (24%, 100%). CONCLUSION: 
      Biomarkers are useful in assessing disease activity, severity and response to 
      therapy in patients with UC. They showed a high degree of correlation with each 
      other.
FAU - Masoodi, Ibrahim
AU  - Masoodi I
AD  - Department of Gastroenterology, Postgraduate Institute of Medical Education and 
      Research (PGIMER), Chandigarh, India.
FAU - Kochhar, Rakesh
AU  - Kochhar R
FAU - Dutta, Usha
AU  - Dutta U
FAU - Vaishnavi, Chetana
AU  - Vaishnavi C
FAU - Prasad, Kaushal K
AU  - Prasad KK
FAU - Vaiphei, Kim
AU  - Vaiphei K
FAU - Kaur, Sukhminder
AU  - Kaur S
FAU - Singh, Kartar
AU  - Singh K
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Gastrointestinal Agents)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EC 3.4.21.- (Lactoferrin)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Biomarkers/analysis/blood
MH  - C-Reactive Protein/*analysis
MH  - Case-Control Studies
MH  - Colitis, Ulcerative/blood/*diagnosis/drug therapy/pathology
MH  - Colonoscopy
MH  - Drug Therapy, Combination
MH  - Feces/*chemistry
MH  - Female
MH  - Gastrointestinal Agents/therapeutic use
MH  - Humans
MH  - Lactoferrin/*analysis
MH  - Male
MH  - Middle Aged
MH  - Peroxidase/*analysis
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - ROC Curve
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2010/02/09 06:00
MHDA- 2010/04/23 06:00
CRDT- 2010/02/09 06:00
PHST- 2010/02/09 06:00 [entrez]
PHST- 2010/02/09 06:00 [pubmed]
PHST- 2010/04/23 06:00 [medline]
AID - JGH6048 [pii]
AID - 10.1111/j.1440-1746.2009.06048.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2009 Nov;24(11):1768-74. doi: 
      10.1111/j.1440-1746.2009.06048.x.